Track topics on Twitter Track topics that are important to you
The National Institute for Health and Care Excellence (NICE) has issued its final appraisal decision (FAD) recommending reimbursement of lenvatinib for the treatment of progressive, locally advanced or metastatic, differentiated...
Original Article: NICE recommends lenvatinib for differentiated thyroid cancerNEXT ARTICLE
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...